UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2026

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________to _________

Commission File Number: 001-42374

SYNERGY CHC CORP.

(Exact name of registrant as specified in its charter)

Nevada		99-0379440
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

770 Roosevelt Trail STE 8 #1016 N. Windham, Maine		04062
(Address of principal executive offices)		(Zip Code)

(207) 321-2350

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common stock, par value $0.00001 per share		SNYR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 11, 2026, there were 15,079,956 shares of common stock, par value $0.00001 per share, of the registrant issued and 14,899,883 shares outstanding.

TABLE OF CONTENTS

PART I-FINANCIAL INFORMATION		1
Item 1. Financial Statements		1
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		25
Item 3. Quantitative and Qualitative Disclosures About Market Risk		29
Item 4. Controls and Procedures		29

PART II-OTHER INFORMATION		30
Item 1. Legal Proceedings		30
Item 1A. Risk Factors		30
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		30
Item 3. Defaults Upon Senior Securities		30
Item 4. Mine Safety Disclosures		30
Item 5. Other Information		30
Item 6. Exhibits		31

SIGNATURES		32

PART I-FINANCIAL INFORMATION

Item 1. Financial Statements.

Synergy CHC Corp.

Condensed Interim Financial Statements

For the Three Months Ended March 31, 2026 and 2025

Unaudited

(Expressed in U.S. Dollars)

MANAGEMENT’S RESPONSIBILITY FOR FINANCIAL
REPORTING CONDENSED INTERIM FINANCIAL REPORTING

The accompanying unaudited condensed interim financial statements of Synergy CHC Corp. (“the Company”) have been prepared by management in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Management acknowledges responsibility for the preparation and presentation of the unaudited condensed interim financial statements, including responsibility for significant accounting estimates and the choice of accounting principles and methods that are appropriate to the Company’s circumstances.

Synergy CHC Corp.

Condensed Consolidated Balance Sheets

	March 31, 2026			December 31, 2025
	(unaudited)
Assets
Current Assets
Cash and cash equivalents	$	292,115		$	2,622,313
Restricted cash		100,000			100,000
Accounts receivable, net		1,268,022			3,203,505
Prepaid expenses (including related party amount of $652,270 and $110,803, respectively)		1,303,173			351,049
Inventory, net		3,381,614			3,737,509
Total Current Assets		6,344,924			10,014,376

Intangible assets, net		116,667			150,000

Total Assets	$	6,461,591		$	10,164,376

Liabilities and Stockholders’ Deficit
Current Liabilities:
Accounts payable and accrued liabilities (including payable to shareholder of $193,641 and $197,512, respectively)	$	4,031,994		$	6,388,219
Income taxes payable		85,811			88,108
Contract liabilities		-			1,526
Short term loans payable, net of debt discount, related party		-			100,000
Current portion of notes payable, net of debt discount		2,730,981			1,658,215
Total Current Liabilities		6,848,786			8,236,068

Long-term Liabilities:
Notes payable, net of debt discount		25,018,055			25,056,446
Total long-term liabilities		25,018,055			25,056,446
Total Liabilities		31,866,841			33,292,514

Commitments and contingencies

Stockholders’ Deficit:
Common stock, $0.00001 par value; 300,000,000 shares authorized; 11,483,926 shares issued; 11,303,853 outstanding		114			114
Additional paid in capital		33,710,857			33,594,550
Common stock to be issued		153,400			-
Accumulated other comprehensive loss		(132,201	)		(154,281	)
Accumulated deficit		(59,009,920	)		(56,441,021	)
Less: Treasury stock (180,073 shares) at cost		(127,500	)		(127,500	)
Total stockholders’ deficit		(25,405,250	)		(23,128,138	)
Total Liabilities and Stockholders’ Deficit	$	6,461,591		$	10,164,376

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

Synergy CHC Corp.

Unaudited Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income

	For the three months ended			For the three months ended
	March 31, 2026			March 31, 2025
Revenue
Product Sales	$	5,492,705		$	6,670,534
License Revenue		-			1,500,000
Total Revenue		5,492,705			8,170,534

Cost of Sales		1,521,910			2,006,513

Gross Profit		3,970,795			6,164,021

Operating expenses
Selling and marketing		2,455,732			2,876,271
General and administrative		2,048,850			1,306,714
Depreciation and amortization		33,333			33,333
Total operating expenses		4,537,915			4,216,318

(Loss) Income from operations		(567,120	)		1,947,703

Other (income) expenses
Interest income		(340	)		(13,882	)
Interest expense		2,012,121			1,095,369
Remeasurement loss on translation of foreign subsidiary		3,718			1,412

Total other expenses		2,015,499			1,082,899

Net (loss) income before income taxes		(2,582,619	)		864,804
Income tax benefit		13,720			11,460

Net (loss) income after tax	$	(2,568,899	)	$	876,264

Net (loss) income per share – basic	$	(0.23	)	$	0.10
Net (loss) income per share – diluted	$	(0.23	)	$	0.10

Weighted average common shares outstanding
Basic		11,303,853			8,560,636
Diluted		11,303,853			8,577,620
Comprehensive (loss) income:
Net (loss) income	$	(2,568,899	)	$	876,264
Foreign currency translation adjustment		22,080			(1,935	)
Comprehensive (loss) income	$	(2,546,819	)	$	874,329

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

Synergy CHC Corp.

Unaudited Condensed Consolidated Statements of Stockholders’ Deficit

	Common stock				Additional Paid in		Accumulated Other Comprehensive Income			Treasury			Accumulated			Total Stockholders’
	Shares		Amount		Capital		(Loss)			stock			Deficit			Deficit
Balance as of December 31, 2024		8,721,818	$	87	$	27,643,660	$	(47,777	)	$	(127,500	)	$	(44,099,813	)	$	(16,631,343	)
Foreign currency translation loss								(1,935	)								(1,935	)
Issuance of common stock for loan financing		30,360		1		117,647											117,648
Net income														876,264			876,264
Balance as of March 31, 2025		8,752,178	$	88	$	27,761,307	$	(49,712	)	$	(127,500	)	$	(43,223,549	)	$	(15,639,366	)

	Common stock				Additional Paid in		Common stock to be		Accumulated Other Comprehensive Income			Treasury			Accumulated			Total Stockholders’
	Shares		Amount		Capital		issued		(Loss)			stock			Deficit			Deficit
Balance as of December 31, 2025		11,483,926	$	114	$	33,594,550	$	-	$	(154,281	)	$	(127,500	)	$	(56,441,021	)	$	(23,128,138	)
Foreign currency translation income										22,080									22,080
Fair value of vested stock options						116,307													116,307
Common stock to be issued for accounts receivable advance financing								153,400											153,400
Net loss																(2,568,899	)		(2,568,899	)
Balance as of March 31, 2026		11,483,926	$	114	$	33,710,857	$	153,400	$	(132,201	)	$	(127,500	)	$	(59,009,920	)	$	(25,405,250	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

Synergy CHC Corp.

Unaudited Condensed Consolidated Statements of Cash Flows

	For the three months ended			For the three months ended
	March 31, 2026			March 31, 2025
Cash Flows from Operating Activities
Net (loss) income	$	(2,568,899	)	$	876,264
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Amortization of debt discount and debt issuance cost		951,942			406,841
Depreciation and amortization		33,333			33,333
Stock based compensation		116,307			-
Foreign currency transaction loss (gain)		2,684			(3,137	)
Remeasurement loss (gain) on translation of foreign subsidiary		3,718			(1,412	)
Changes in operating assets and liabilities:
Accounts receivable		1,935,483			940,519
Other receivables		-			144,637
Loan receivable, related party		-			(833	)
Inventory		355,895			(629,935	)
Prepaid expenses		(410,657	)		(114,787	)
Prepaid expense, related party		(541,467	)		(195,913	)
Income taxes payable		(2,297	)		(165,413	)
Contract liabilities		(1,526	)		(24,216	)
Accounts payable and accrued liabilities		(1,915,323	)		(2,218,041	)
Accounts payable, related party		(3,871	)		129,312
Net cash used in operating activities		(2,044,678	)		(822,781	)

Cash Flows from Investing Activities		-			-

Cash Flows from Financing Activities
Advances from related party		-			135,000
Repayment of notes payable, related party		(100,000	)		-
Proceeds from notes payable		2,660,000			1,496,250
Payment of loan financing fees		(55,000	)		-
Repayment of notes payable		(2,812,600	)		(1,316,572	)
Net cash (used in) provided by financing activities		(307,600	)		314,678

Effect of exchange rate on cash, cash equivalents and restricted cash		22,080			(1,935	)
Net decrease in cash, cash equivalents and restricted cash		(2,330,198	)		(510,038	)

Cash and restricted cash, beginning of year		2,722,313			787,920
Cash and restricted cash, end of period	$	392,115		$	277,882

Supplemental Disclosure of Cash Flow Information:
Cash paid during the period for:
Interest	$	392,846		$	573,529
Income taxes	$	-		$	-

Supplemental Disclosure of Noncash Investing and Financing Activities:
Issuance of common stock for accounts receivable advance financing	$	-		$	117,648
Loan financing fees, accrued	$	110,000		$	-
Capitalized interest on senior debt	$	400,033		$	-
Common stock to be issued for accounts receivable advance financing	$	153,400		$	-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

Synergy CHC Corp.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1 – Nature of the Business

Synergy CHC Corp. (“Synergy”, “we”, “us”, “our” or the “Company”) (formerly Synergy Strips Corp.) was incorporated on December 29, 2010 in Nevada under the name “Oro Capital Corporation.” On April 21, 2014, the Company changed its fiscal year end from July 31 to December 31. On April 28, 2014, the Company changed its name to “Synergy Strips Corp.” On August 5, 2015, the Company changed its name to “Synergy CHC Corp.”

The Company is a consumer health care company that is in the process of building a portfolio of best-in-class consumer product brands. Synergy’s strategy is to grow its portfolio both organically and by further acquisitions.

Synergy is the sole owner of four subsidiaries: NomadChoice Pty Ltd., Hand MD Corp., Synergy CHC Inc. and Synergy CHC Mexico, and the results have been consolidated in these statements.

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation

The accompanying condensed consolidated financial statements as of March 31, 2026 and for the three months ended March 31, 2026 and 2025 are unaudited. The accompanying condensed consolidated financial statements have been prepared in conformity with US GAAP. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2026 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2026. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2025 and footnotes thereto, included in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 1, 2026.

All amounts referred to in the notes to the condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise.

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates included are assumptions about collection of accounts receivable, current income taxes, deferred income taxes valuation allowance, useful life of intangible assets, impairment analysis of intangible assets, estimates used in the fair value calculation of stock based compensation, assumptions used in Black-Scholes-Merton, or BSM, valuation methods, such as expected volatility, risk-free interest rate and expected dividend rate, accrual of sales returns, and accrual of legal expense. The results of any changes in accounting estimates are reflected in the financial statements in the period in which the changes become evident. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the period that they are determined to be necessary.

Cash and Cash Equivalents

The Company considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid investments with maturities of three months or less, when purchased, to be cash and cash equivalents. As of March 31, 2026 and December 31, 2025, the Company had no cash equivalents. The Company maintains its cash in banks insured by the Federal Deposit Insurance Corporation (FDIC) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. At March 31, 2026 and December 31, 2025, the uninsured balances amounted to $126,445 and $2,450,399, respectively.

Restricted Cash

The following table provides a reconciliation of cash and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows.

	March 31, 2026		December 31, 2025

Cash	$	292,115	$	2,622,313
Restricted cash		100,000		100,000
Total cash and restricted cash shown in the statement of cash flows	$	392,115	$	2,722,313

Amounts included in restricted cash represent amounts held for credit card collateral.

Intangible Assets

The Company evaluates the recoverability of intangible assets periodically and takes into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. All of the intangible assets are subject to amortization. Intangible assets are amortized on a straight-line basis over the useful lives.

Long-lived Assets

Long-lived assets include intangible assets other than those with indefinite lives. The Company assesses the carrying value of its long-lived asset groups when indicators of impairment exist and recognizes an impairment loss when the carrying amount of a long-lived asset is not recoverable when compared to undiscounted cash flows expected to result from the use and eventual disposition of the asset.

Indicators of impairment include significant underperformance relative to historical or projected future operating results, significant changes in the Company’s use of the assets or in its business strategy, loss of or changes in customer relationships and significant negative industry or economic trends. When indications of impairment arise for a particular asset or group of assets, the Company assesses the future recoverability of the carrying value of the asset (or asset group) based on an undiscounted cash flow analysis. If carrying value exceeds projected, net, undiscounted cash flows, an additional analysis is performed to determine the fair value of the asset (or asset group), typically a discounted cash flow analysis, and an impairment charge is recorded for the excess of carrying value over fair value.

Revenue Recognition

The Company recognizes revenue in accordance with the Financial Accounting Standards Board’s (“FASB”), Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

The Company recognizes revenue upon shipment from its fulfillment centers. Certain of the Company’s distributors may also perform a separate function as a co-packer on the Company’s behalf. In such cases, ownership of and title to the Company’s products that are co-packed on the Company’s behalf by those co-packers who are also distributors, passes to such distributors when the Company is notified by them that they have taken transfer or possession of the relevant portion of the Company’s finished goods. Freight billed to customers is presented as revenues, and the related freight costs are presented in selling and marketing expense. Cancelled orders are refunded if not already dispatched, refunds are only paid if stock is damaged in transit, discounts are only offered with specific promotions and orders will be refilled if lost in transit. The Company recognizes revenue for its digital products in the month the download by the customer occurs.

All product sales were initiated based upon the retailer’s purchase orders at a fixed transaction price and revenues recognized when the products were shipped to the Company’s customers.

The Company accounts for its intellectual property (IP) license revenue, which provides the Company’s customer with rights to use the Company’s IP, in accordance with ASC 606. A license may be perpetual or time limited in its application. In accordance with ASC 606, the Company will continue to recognize revenue from IP license at the time of delivery when the customer accepts control of the IP, as the IP is functional without professional services, updates and technical support. The Company has concluded that its IP license is distinct as the customer can benefit from the functional IP on its own. Therefore, the Company has determined the right to use its IP was satisfied at a point in time (on the date the rights to the IP were granted).

Contract Assets

The Company does not have any contract assets such as work-in-process. All trade receivables on the Company’s condensed consolidated balance sheet are from contracts with customers.

Contract Costs

Costs incurred to obtain a contract are capitalized if the Company expects to recover those costs. As a practical expedient, costs to obtain a contract that are short term in nature are expensed as incurred. The Company does not have any contract costs capitalized as of March 31, 2026 and December 31, 2025.

Contract Liabilities

The Company’s contract liabilities consist of advance customer payments. Contract liability results from transactions in which the Company has been paid for products by customers, but for which all revenue recognition criteria have not yet been met. Once all revenue recognition criteria have been met, the contract liabilities are recognized.

	March 31, 2026			December 31, 2025

Beginning balance	$	1,526		$	24,252
Additions		-			1,526
Recognized as revenue		(1,526	)		(24,252	)
Ending balance	$	-		$	1,526

Accounts receivable

Accounts receivable are generally unsecured. The Company establishes an allowance for doubtful accounts receivable based on the age of outstanding invoices and management’s evaluation of collectability. Accounts are written off after all reasonable collection efforts have been exhausted and management concludes that likelihood of collection is remote. Any future recoveries are applied against the allowance for doubtful accounts. As of March 31, 2026 and December 31, 2025, the allowance for doubtful accounts was $43,856 and $377,579, respectively.

Advertising Expense

The Company expenses marketing, promotions and advertising costs as incurred. Such costs are included in selling and marketing expense in the accompanying condensed consolidated statements of operations.

Research and Development

Costs incurred in connection with the development of new products and processing methods are charged to general and administrative expenses as incurred.

Income Taxes

The Company utilizes FASB ASC 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized.

The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of 100% has been established due to the uncertainty of the Company’s realization of the net operating loss carry forward prior to its expiration.

NomadChoice Pty Ltd, the Company’s wholly-owned subsidiary is subject to income taxes in Australia, the jurisdictions in which it operates. Significant judgment is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The company recognizes liabilities for anticipated tax audit issues based on the Company’s current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made.

Synergy CHC Inc., a wholly-owned foreign subsidiary, is subject to income taxes in Canada, the jurisdictions in which it operates. Significant judgment is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The company recognizes liabilities for anticipated tax audit issues based on the Company’s current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made.

Synergy CHC Mexico is a wholly-owned foreign subsidiary, and is subject to income taxes in Mexico, the jurisdiction in which it operates. Significant judgment is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The company recognizes liabilities for anticipated tax audit issues based on the Company’s current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made.

Net Earnings (Loss) Per Common Share

The Company computes earnings per share under ASC subtopic 260-10, Earnings Per Share. Basic earnings (loss) per share is computed by dividing the net income (loss) (the numerator) by the weighted average number of shares of common stock outstanding (the denominator) during the reporting periods. Diluted earnings per share is computed by increasing the denominator by the weighted average number of additional shares that could have been outstanding from securities convertible into common stock (using the “treasury stock” method), unless their effect on net income per share is anti-dilutive. As of March 31, 2026 and 2025, options to purchase 1,200,000 and 252,102 shares of common stock, respectively, were outstanding. As of March 31, 2026 and 2025, warrants to purchase 3,156,000 and 103,500 shares of common stock, respectively, were outstanding.

The following is a reconciliation of the number of shares used in the calculation of basic and diluted (loss) earnings per share for the three months ended March 31, 2026 and 2025:

	For the three months ended
	March 31, 2026			March 31, 2025

Net (loss) income after tax	$	(2,568,899	)	$	876,264

Weighted average common shares outstanding		11,303,853			8,560,636
Incremental shares from the assumed exercise of dilutive stock options		-			16,984
Dilutive potential common shares		11,303,853			8,577,620

Net (loss) earnings per share:
Basic	$	(0.23	)	$	0.10
Diluted	$	(0.23	)	$	0.10

The following securities were not included in the computation of diluted net (loss) earnings per share as their effect would have been antidilutive, or are non-exercisable:

	For the three months ended
	March 31, 2026		March 31, 2025

Options to purchase common stock		1,200,000		235,118
Warrants to purchase common stock		3,156,000		103,500

Fair Value Measurements

The Company measures and discloses the fair value of assets and liabilities required to be carried at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value, establishes a framework for measuring fair value, and enhances fair value measurement disclosure.

ASC 825 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825 establishes three levels of inputs that may be used to measure fair value:

Level 1 -

Quoted prices for identical assets or liabilities in active markets to which the Company has access at the measurement date.

Level 2 -

Inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3 -

Unobservable inputs for the asset or liability.

The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

Our financial instruments consisted primarily of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities and short term and long-term loans payable. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.

As of both March 31, 2026 and December 31, 2025, the Company has determined that there were no assets or liabilities measured at fair value on a recurring basis.

Inventory

Inventory consists of raw materials, components and finished goods. The Company’s inventory is stated at the lower of cost (FIFO cost basis) or net realizable value. Finished goods include the cost of labor to assemble the items.

Foreign Currency Translation

The functional currency of one of the Company’s foreign subsidiaries (NomadChoice Pty Ltd.) is the U.S. Dollar. The Company’s foreign subsidiary maintains its records using local currency (Australian Dollar). All monetary assets and liabilities of the foreign subsidiary were translated into U.S. Dollars at quarter end exchange rates, non-monetary assets and liabilities of the foreign subsidiary were translated into U.S. Dollars at transaction day exchange rates.

Income and expense items related to non-monetary items were translated at exchange rates prevailing during the transaction date and other incomes and expenses were translated using average exchange rate for the period. The resulting translation adjustments, net of income taxes, were recorded in statements of operations as Remeasurement gain or loss on translation of foreign subsidiary.

The functional currency of one of the Company’s foreign subsidiaries (Synergy CHC Inc.) is the Canadian Dollar (CAD). The Company’s foreign subsidiary maintains its records using local currency (CAD). All assets and liabilities of the foreign subsidiary were translated into U.S. Dollars at period end exchange rates and stockholders’ equity is translated at the historical rates. Income and expense items were translated using average exchange rate for the period. The resulting translation adjustments, net of income taxes, are reported as other comprehensive income and accumulated other comprehensive income in the stockholder’s equity in accordance with ASC 220 – Comprehensive Income.

The functional currency of the Company’s other foreign subsidiary (Synergy CHC Mexico) is the Mexican Peso (MXN). The Company’s foreign subsidiary maintains its records using local currency (MXN). All assets and liabilities of the foreign subsidiary were translated into U.S. Dollars at period end exchange rates and stockholders’ equity is translated at the historical rates. Income and expense items were translated using average exchange rate for the period. The resulting translation adjustments, net of income taxes, are reported as other comprehensive income and accumulated other comprehensive income in the stockholder’s equity in accordance with ASC 220 – Comprehensive Income.

The exchange rates used to translate amounts in AUD, CAD and MXN into USD for the purposes of preparing the condensed consolidated financial statements were as follows:

Balance sheet:

	March 31,		December 31,
	2026		2025
Period-end AUD: USD exchange rate	$	0.6844	$	0.6696
Period-end CAD: USD exchange rate	$	0.7174	$	0.7296
Period-end MXN: USD exchange rate	$	0.0551	$	0.0555

Income statement:

	March 31,		March 31,
	2026		2025
Average three months AUD: USD exchange rate	$	0.6941	$	0.6272
Average three months CAD: USD exchange rate	$	0.7290	$	0.6968
Average three months MXN: USD exchange rate	$	0.0570	$	-

Translation gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are translated into either Australian Dollars, Canadian Dollars or Mexican Pesos, as the case may be, at the rate on the date of the transaction and included in the results of operations as incurred.

Concentrations of Credit Risk

In the normal course of business, the Company provides credit terms to its customers; however, collateral is not required. Accordingly, the Company performs credit evaluations of its customers and maintains allowances for possible losses which, when realized, were within the range of management’s expectations. From time to time, a higher concentration of credit risk exists on outstanding accounts receivable for a select number of customers due to individual buying patterns.

Warehousing costs

Warehouse costs include all third-party warehouse rent fees and are charged to selling and marketing expenses as incurred. Any additional costs relating to assembly or special pack-outs of the Company’s products are charged to cost of sales.

Product display costs

All displays manufactured and purchased by the Company are for placement of product in retail stores. This also includes all costs for display execution and setup and retail services are charged to cost of sales and expensed as incurred.

Cost of Sales

Cost of sales includes the purchase cost of products sold, all costs associated with getting the products into the retail stores including buying and transportation costs and the hosting of the Company’s online Application.

Debt Issuance Costs

Debt issuance costs consist primarily of arrangement fees, professional fees and legal fees. These costs are netted off with the related loan and are being amortized to interest expense over the term of the related debt facilities.

Shipping Costs

Shipping and handling costs billed to customers are recorded in sales. Shipping costs incurred by the company are recorded in selling and marketing expenses.

Related parties

Parties are considered to be related to the Company if the parties that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.

Segment Reporting

Segment identification and selection is consistent with the management structure used by the Company’s chief executive officer who is the Chief Operating Decision Maker (CODM) to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company’s management structure and method of internal reporting, the Company has one operating segment. The Company derives its revenue from the sale of nutraceuticals. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the segment and decides how to allocate resources based on net income that also is reported on the income statement as consolidated net income. The measure of segment assets is reported on the balance sheet as total consolidated assets. Significant segment expenses include retailer promotions, freight and fulfillment, marketing and salaries. The Company’s CODM reviews financial information presented and decides how to allocate resources based on net income. The Company does not have any intra-entity sales or transfers. The Company’s CODM does not review operating results on a disaggregated basis; rather, the CODM reviews operating results on an aggregated basis.

Presentation of Financial Statements – Going Concern

Going Concern Evaluation

In connection with preparing unaudited condensed consolidated financial statements for the three months ended March 31, 2026, management evaluated whether there were conditions and events, considered in the aggregate, that raised substantial doubt about the Company’s ability to continue as a going concern within one year from the date that the unaudited condensed consolidated financial statements are issued.

The Company considered the following:

●

At March 31, 2026, the Company had an accumulated deficit of $59,009,920.

●

At March 31, 2026, the Company had a decrease in net revenue of $2,677,829.

●

At March 31, 2026, the Company had a decrease in net income of $3,445,163.

●

At March 31, 2026, the Company had a working capital deficit of $503,862.

●

During the three months ended March 31, 2026, the Company used $2,044,678 in operating activities.

Ordinarily, conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern relate to the entity’s ability to meet its obligations as they become due.

The Company evaluated its ability to meet its obligations as they become due within one year from the date that the unaudited condensed consolidated financial statements are issued by considering the following:

●

The Company entered into a second amendment with its current lender which adjusts various covenants and payment terms.

●

The Company laid off 13 employees in order to right size its overhead expenses.

●

The Company has established an at-the-market (“ATM”) equity offering program pursuant to which it may issue and sell shares of its common stock from time to time, subject to market conditions and other factors. Subsequent to March 31, 2026 the Company has drawn down $2,673,201 in gross proceeds.

●

The Company has entered into an equity purchase agreement (“ELOC”), pursuant to which it may issue and sell shares of its common stock from time to time, subject to market conditions and other factors (see Note 16).

Management concluded that the above factors alleviate doubts about the Company’s ability to generate enough cash from operations and other available sources to satisfy its obligations for the next twelve months from the issuance date.

Recent Accounting Pronouncements

In October 2023, the FASB issued ASU No. 2023-06, “Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative” (“ASU 2023-06”). ASU 2023-06 amends U.S. GAAP to reflect updates and simplifications to certain disclosure and presentation requirements referred to FASB by the SEC. The targeted amendments incorporate 14 of the 27 disclosures referred by the SEC into codification. Each amendment in ASU 2023-06 is effective on either the date on which the SEC’s removal of the related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, or on June 30, 2027, if the SEC has not removed the requirements by that date. The Company is currently evaluating the impact this update will have on its Condensed Consolidated Financial Statements.

In July 2025, the FASB issued ASU No. 2025-05, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets” (“ASU 2025-05”). ASU 2025-05 provides a practical expedient to assume that conditions as of the balance sheet date remain unchanged over the life of the asset when estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for under Topic 606. The amendments are effective for the fiscal years beginning after December 15, 2025 and interim periods within those annual reporting periods, with early adoption permitted. The adoption of ASU No. 2025-05 has not affected the Company’s Condensed Consolidated Financial Statements.

Note 3 – Income Taxes

Deferred income taxes arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or noncurrent depending on the periods in which the temporary differences are expected to reverse. The Company does not have any uncertain tax positions.

For U.S. purposes, the Company has not completed its evaluation of net operating loss (NOL) utilization limitations under Internal Revenue Code, as amended (the “Code”) Section 382/383, change of ownership rules. If the Company has had a change in ownership, the NOLs would be limited or eliminated, as to the amount that could be utilized each year, based on the Code. NOLs attributable to Breakthrough Products, Inc., which are the majority of the Company’s domestic NOLs are Separate Return Limitation Year (SRLY) NOLs. Such losses may generally not be available for use (limited or eliminated).

The Company has not filed its State & Local Income/Franchise tax returns in states it is required to file, as such returns and liability remain open. The Company does not expect this to be a significant liability.

The table below summarizes the differences between the U.S. statutory federal rate and the Company’s estimated effective tax rate for the three months ended March 31, 2026 and 2025:

	March 31, 2026 ($)			March 31, 2026			March 31, 2025 ($)			March 31, 2025
U.S. Statutory Rate	$	(542,350	)		(21	)%	$	181,609			21	%

AU/CA/MXN rates in excess of the US rate		(30,868	)		(1	)%		(4,593	)		(1)	%

Increase (decrease) in valuation allowance		590,370			22	%		(188,477	)		(21	)%
Permanent differences		-			-	%		-			-	%
Prior period true up		(3,432	)		(1	)%		-			-	%
Total provision for income taxes	$	(13,720	)		(1	)%	$	(11,460	)		(1	)%

The Company has deferred tax assets, which have been fully reserved, as follows as of March 31, 2026 and December 31, 2025:

	March 31, 2026			December 31, 2025
Net operating Losses	$	10,703,792		$	11,993,073

Obsolete inventory		26,326			26,326
Nonstatutory stock options		548,931			515,319
Other		57,750			43,313
Impairment of intangible asset		220,150			220,150
Amortization		-			-
Bad debt reserve		-			-
Other		-			2,815,819
Deferred tax asset		11,556,949			15,614,000
Valuation allowance for deferred tax assets		(11,556,949	)		(15,614,000	)
Net deferred tax assets	$	-		$	-

The Company had tax benefit of $13,720 and $11,460 for the three months ended March 31, 2026 and 2025, respectively.

Income tax provision (benefit) consists of the following for the three months ended March 31, 2026 and 2025:

	For the Three Months Ended March 31,
Income tax provision (benefit):	2026			2025
Current
Federal	$	-		$	-
State		-
Foreign		(13,720	)		(11,460	)
Total Current		(13,720	)		(11,460	)
Deferred
Federal		-			-
State		-			-
Foreign		-			-
Total Deferred		-			-

Total income tax benefit	$	(13,720	)	$	(11,460	)

The table below summarizes the (loss) income before taxes for domestic and foreign jurisdictions:

	March 31, 2026			March 31, 2025

Domestic (U.S.)	$	(2,239,496	)	$	916,230
Foreign		(343,123	)		(51,426	)
Total	$	(2,582,619	)	$	864,804

The table below summarizes the income tax expense for the three months ended March 31, 2026 and 2025:

	March 31, 2026			March 31, 2025
Federal	$	-		$	-
State		-
Foreign		(13,720	)		(11,460	)
Total	$	(13,720	)	$	(11,460	)

The Company also has net operating loss carryforwards of approximately $59,582,000 and approximately $57,000,000 (United States, Canada and Australia) included in the deferred tax assets for March 31, 2026 and December 31, 2025, respectively, the majority attributable to the acquisition of Breakthrough Products, Inc. However, due to limitations of carryover attributes and separate return limitation year rules, it is unlikely the company will benefit from the NOLs and thus management has determined a 100% valuation allowance is required. Further, the Company has not completed an evaluation of the NOLs attributable to Breakthrough Products, Inc. at the date of this report.

Note 4 – Accounts Receivable

Accounts receivable, net of allowances for doubtful accounts, consisted of the following:

	March 31, 2026			December 31, 2025
Trade accounts receivable	$	1,311,878		$	3,581,084
Less allowances		(43,856	)		(377,579	)
Total accounts receivable, net	$	1,268,022		$	3,203,505

During the three months ended March 31, 2026 and 2025, the Company charged $0 to bad debt expense. During the three months ended March 31, 2026 the Company wrote off $333,720 of allowance for doubtful accounts to accounts receivable that it deemed uncollectible. The Company’s accounts receivables fluctuate due to increasing or decreasing shipments and promotions that it runs with its customers. The Company records an allowance for doubtful accounts when it becomes more likely than not that an account is uncollectible.

Note 5 – Prepaid Expenses

At March 31, 2026 and December 31, 2025, prepaid expenses consisted of the following:

	March 31, 2026		December 31, 2025
Advances for inventory	$	195,234	$	168,174
Insurance		79,103		17,081
Accounting		45,000		-
Contract employee, related party		638,203		110,803
Rent, related party		14,067		-
Legal expenses		105,341		-
Conferences		24,614		11,333
Professional fees		89,405		-
IT expenses		60,166		43,132
Payroll		51,504		-
Miscellaneous		536		526
Total	$	1,303,173	$	351,049

Note 6 – Concentration of Credit Risk

Cash and cash equivalents

The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (FDIC) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. At March 31, 2026 and December 31, 2025, the uninsured balances amounted to $126,445 and $2,450,399 respectively.

Accounts receivable

As of March 31, 2026 and December 31, 2025, three customers and one customer accounted for 58% and 71%, respectively, of the Company’s trade accounts receivable.

Major customers

For the three months ended March 31, 2026, three customers accounted for approximately 85% of the Company’s net revenue. For the three months ended March 31, 2025, three customers accounted for approximately 71% of the Company’s net revenue. Substantially all of the Company’s business is with companies in North America.

Accounts payable

As of March 31, 2026 and December 31, 2025, two vendors accounted for 57% and 64%, respectively, of the Company’s accounts payable.

Major suppliers

For the three months ended March 31, 2026, one supplier accounted for approximately 38% of the Company’s purchases. For the three months ended March 31, 2025, two suppliers accounted for approximately 44% of the Company’s purchases.

Note 7 – Inventory

Inventory consists of finished goods, components and raw materials. The Company’s inventory is stated at the lower of cost (FIFO cost basis) or net realizable value.

The carrying value of inventory consisted of the following:

	March 31, 2026		December 31, 2025
Finished goods	$	2,993,516	$	3,325,093
Components		302,641		412,416
Ingredients		85,457		-
Total inventory	$	3,381,614	$	3,737,509

During the three months ended March 31, 2026 and 2025, the Company had no inventory write-offs.

Note 8 – Intangible Assets

	March 31, 2026			December 31, 2025

License Fee	$	450,000		$	450,000
Less accumulated amortization		(333,333	)		(300,000	)
Intangible assets, net	$	116,667		$	150,000

Amortization for both the three months ended March 31, 2026 and 2025 was $33,333.

The estimated aggregate amortization expense over each of the next five years is as follows:

2026 (remaining)		$	100,000
2027			16,667

Note 9 – Related Party Transactions

The Company paid consulting fees through March 2026 to a company owned by Mr. Jack Ross, Chief Executive Officer of the Company. The Company advanced $377,400 of consulting fees and expensed $225,000 of consulting fees during the three months ended March 31, 2026. The Company advanced $180,000 in prepaid consulting fees during the three months ended March 31, 2025. The Company paid a bonus of $400,000 for 2026 to the related party. The prepaid balance as of March 31, 2026 and December 31, 2025 was $638,203 and $110,803, respectively. During March 2026, the Company paid $12,500 for a vehicle allowance, of which $7,500 has been expensed and $5,000 remains in prepaid expenses. During the three months ended March 31, 2026, the Company repaid a short-term note of $100,000. The balance owed as of March 31, 2026 was $0. During the three months ended March 31, 2025, the Company was advanced $135,000 in the form of a short-term note. The balance owed as of March 31, 2025 was $135,000.

The Company paid rent through March 2026 to a company owned by Mr. Jack Ross, Chief Executive Officer of the Company. The Company expensed $58,824 Canadian Dollars ($42,885 US Dollars) for the three months ended March 31, 2026, leaving a prepaid balance of $19,608 Canadian Dollars ($14,067 US Dollars).

On December 23, 2016, the Company entered into an agreement with Knight Therapeutics (“Knight”), a shareholder of the Company, for the distribution rights of FOCUSfactor in Canada. In conjunction with this agreement, the Company is required to pay Knight a distribution fee equal to 30% of gross sales for sales achieved through a direct sales channel and 5% of gross sales for sales achieved through retail sales. The minimum due to Knight under this agreement is $100,000 Canadian dollars. As of both March 31, 2026 and December 31, 2025, the total outstanding balance was $269,920 Canadian dollars. In US Dollars, the total outstanding balance was $193,641 and $196,934 as of March 31, 2026 and December 31, 2025, respectively.

The Company expensed royalty of $0 and $4,549 for the three months ended March 31, 2026 and 2025, respectively. At March 31, 2026 and December 31, 2025, the Company owed Knight $0 and $578, respectively, in connection with a royalty distribution agreement.

Note 10 – Accounts Payable and Accrued Liabilities

As of March 31, 2026 and December 31, 2025, accounts payable and accrued liabilities consisted of the following:

	March 31, 2026		December 31, 2025
Accrued payroll	$	405,723	$	316,580
Legal fees		260,000		233,199
Commissions		229,412		297,831
Manufacturers		1,202,911		1,664,299
Promotions		686		1,126,523
Accounting Fees		86,712		53,683
Freight		169,952		274,735
Royalties, shareholder		193,641		197,512
Warehousing		516,679		894,161
Sales taxes		1,145		106,909
Payroll taxes		308,598		446,521
Professional Fees		26,400		-
Interest		181,904		300,397
Lender fees		325,000		325,000
Others		123,231		150,867
Total	$	4,031,994	$	6,388,219

The Company has estimated and accrued for its sales tax liability at $1,145 and $355 for the parent entity as of March 31, 2026 and December 31, 2025, respectively.

Note 11 – Notes Payable

The Company’s notes payable at March 31, 2026 and December 31, 2025 are as follows:

	March 31, 2026			December 31, 2025
$2,000,000 and $6,000,000 Notes	$	9,595,223		$	9,595,223
$3,024,000 November 12, 2025 Accounts Receivable Advance		-			2,436,000
$4,032,000 March 10, 2026 Accounts Receivable Advance		3,830,400			-
$17,500,000 May 2025 Loan		17,725,033			17,500,000
		31,150,656			29,531,223
Unamortized debt issuance cost and debt discount		(3,401,620	)		(2,816,562	)
Total		27,749,036			26,714,661

Current portion, other		(2,730,981	)		(1,658,215	)
Long-term portion, other	$	25,018,055		$	25,056,446

$2,000,000 February 10, 2022 Loan:

On February 10, 2022, the Company entered into a promissory note for $2,000,000 with an individual which was to be repaid with subsequent financing.

Subsequently and pursuant to the modification agreement entered into on June 14^th, 2023, effective September 9, 2022, the promissory loan would bear all the same characteristics as the additional $6,000,000 loan noted below.

$6,000,000 March 8, 2022 Loans:

On March 8, 2022, the Company entered into Securities Purchase Agreements with debenture holders for the Senior Subordinated Debentures in the amount of $6,000,000 with an original maturity date of September 8, 2022 and warrants with a term of 3 years. The Senior Subordinated Debentures were modified on June 14, 2023 in conjunction with the promissory note.

On March 31, 2024, the Company entered into a Modification Agreement in relation to this loan, which consolidated it with the $2,000,000 February 10, 2022 loan above.

On May 30, 2025, the Company entered into a Subordination Agreement in relation to this loan, whereby this loan becomes subordinated debt to the senior lender ($17,500,000 May 2025 Loan). This loan may only be repaid based on certain conditions which must be met before payment can be made. There is no maturity date on this loan, and bears interest at 12% per annum.

“Interest Payment Conditions” means with respect to any payment of interest on any Sanders Note, the satisfaction of the following conditions:

(a)	as of the date of any such interest payment and immediately after giving effect thereto, no Default or Event of Default has occurred and is continuing;

(b)	Liquidity (prior to and after giving effect to such payment) shall not be less than $2,000,000;

(c)

the Fixed Charge Coverage Ratio of the Borrower and its Subsidiaries for the period of 12 fiscal months of the Borrower and its Subsidiaries most recently ended prior to such payment (and, for the avoidance of doubt, without giving effect to such payment for purposes of determining Consolidated Net Interest Expense), shall be not less than 1.20 to 1.00; and

(d)	the Administrative Agent shall have received a certificate of an Authorized Officer of the Borrower certifying as to compliance with the preceding clauses and demonstrating (in reasonable detail) the calculation required thereby.

“Principal Payment Conditions” means with respect to any payment or prepayment of principal on any Sanders Note, the satisfaction of the following conditions:

(a)	as of the date of any such principal payment and immediately after giving effect thereto, no Default or Event of Default has occurred and is continuing;

(b)	Liquidity (prior to and after giving effect to such payment) shall not be less than $4,000,000;

(c)

(d)	the Consolidated Senior Net Leverage Ratio of the Borrower and its Subsidiaries as of the end of such fiscal quarter of the Borrower ending on or most recently preceding the date of such payment or prepayment was less than 2.75 to 1.00;

(e)	such payment or prepayment is made using only Net Cash Proceeds of an Equity Issuance which are not required to be applied as a mandatory prepayment pursuant to Section 2.5(c)(v) in an amount not to exceed fifty percent (50%) of such Net Cash Proceeds; and

(f)	the Administrative Agent shall have received a certificate of an Authorized Officer of the Borrower certifying as to compliance with the preceding clauses and demonstrating (in reasonable detail) the calculation required thereby.

On April 28, 2025, the Company entered into Assignment, Assumption and Release Agreement with the holder to release Jack Ross (CEO of the Company) from the obligation to personally grant warrants struck at $0.01 penny per share, covering 10% of his stock to the lender for non-payment of principal amount plus loan renegotiation fees by December 31, 2024. The Company issued 441,178 shares valued at $847,062 to the lender for releasing Jack Ross (CEO) from this obligation.

During March 2026, the Company was notified that this lender believed this loan had a maturity date of March 31, 2026 and they did not intend to grant an extension on the maturity date. Due to this loan being fully subordinated to the senior lender, the Company does not believe this loan has any maturity date while the senior debt is outstanding.

$17,500,000 May 2025 Loan:

On May 30, 2025, Synergy CHC Corp. (the “Company”) entered into a term loan credit agreement (the “Credit Agreement”) with ACP Agency, LLC (“ACP”). The Credit Agreement consists of a $15.0 million term loan (the “Term Loan”), up to $2.5 million in a committed delayed draw facility (the “Delayed Draw Facility”), and up to $2.5 million in an uncommitted term loan incremental facility (the “Incremental Facility”), which facilities are secured by all of the assets of the Company and certain of its subsidiaries; including, without limitation, a pledge of the Company’s equity interests in its subsidiaries and their respective rights to intellectual property. Further, the obligations of the Company under the Credit Agreement are guaranteed by the Company and certain of its subsidiaries. The proceeds of the Term Loan are to be used to repay existing indebtedness of the Company, pay related fees and transaction costs, and provide working capital to the Company. The proceeds of the Delayed Draw Facility are to be used to pay off all indebtedness owed by the Company pursuant to certain settlement agreements. All capitalized words used but not defined herein have the meanings assigned in the Credit Agreement.

The Credit Agreement has customary representations, warranties and covenants including restrictions on indebtedness, liens, restricted payments and dividends, investments, asset sales and similar covenants and contains customary events of default. The Credit Agreement also contains covenants requiring the Company and its subsidiaries to maintain a maximum (x) consolidated senior net leverage ratio of (i) 3.25:1.00 for the quarter ending September 30, 2025, (ii) 3.25:1.00 for the quarter ending December 31, 2025, (iii) 3.00:1.00 for the quarter ending March 31, 2026, (iv) 2.75:1.00 for the quarter ending June 30, 2026, (v) 2.75:1.00 for the quarter ending September 30, 2026, and (vi) 2.50:1.00 for the quarter ending December 31, 2026 and each fiscal quarter ended thereafter and (y) a fixed charge coverage ratio of 1.20 for the quarter ending September 30, 2025 and each fiscal quarter ended thereafter.

Of the Term Loan, $175,000 is subject to repayment on each of January 1, 2026, April 1, 2026, July 1, 2026 and October 1, 2026 and the remaining balance is to be repaid in the amount of $350,000 beginning January 1, 2027 and the first day of each quarter thereafter. The Term Loan bears interest at a rate equal to the Term SOFR rate plus 8.50%. The Delayed Draw Facility and Incremental Facility, if applicable, shall bear interest following any advance of proceed thereunder, at a rate of either (x) (i) Term SOFR rate plus (ii) 8.5%, or (y) (i) a reference rate equal to the greater of (a) 6.0% per annum, (b) the federal funds rate plus 0.50% per annum, (c) the Term SOFR rate plus 1% per annum, and (d) the rate last quoted by The Wall Street Journal as the “Prime Rate” in the United States, plus (ii) 7.50%.

The Company received $15,000,000 in May 2025 on the initial draw and $2,500,000 in June 2025 on a delayed draw. The proceeds of the loan were used to pay out existing debt. The Company recorded $2,385,954 as original debt discount. The Company recognized $155,943 as amortization during the three months ended March 31, 2026. The unamortized balance amounts to $2,034,500 at March 31, 2026.

On March 24, 2026, the Company entered into a second amendment (the “Second Amendment”) to its term loan credit agreement, dated May 30, 2025 (as previously amended, the “Credit Agreement”, and as amended by the Second Amendment, the “Amended Credit Agreement”), with ACP Agency, LLC (“ACP”), as administrative agent and collateral agent, and the lenders party thereto. The Second Amendment amends certain provisions of the Credit Agreement, including provisions relating to the amortization schedule for the term loan, interest payment mechanics, pricing, the application of equity issuance proceeds, limitations on the Company’s ability to elect Term SOFR-based interest, certain covenants, certain financial covenant levels and/or testing periods, and certain fee and expense provisions, as well as related Events of Default provisions. All capitalized terms used but not defined herein have the meanings assigned in the Amended Credit Agreement.

The Amended Credit Agreement provides for scheduled principal payments of $175,000 on each of July 1, 2026 and October 1, 2026, followed by a scheduled principal payment of $525,000 on January 1, 2027, and scheduled principal payments of $350,000 beginning April 1, 2027 and on the first day of each quarter thereafter.

The Amended Credit Agreement adds an Applicable Margin step-up pursuant to which, if the Company fails on or before September 30, 2026 to raise at least $10,000,000 of Net Cash Proceeds from Equity Issuances made on or after the Second Amendment Effective Date (and apply such proceeds as required under the Credit Agreement), then commencing October 1, 2026 the Applicable Margin will increase by 2.00% per annum for the applicable Loans until the Company satisfies that $10,000,000 equity raise condition and applies such proceeds as required. In addition, the Second Amendment modifies interest payment mechanics by requiring that the interest payment due on March 2, 2026 be paid in kind by capitalizing such interest and adding it to the then-outstanding principal amount of the Term Loan and permitting the Company, at its election and subject to providing the required notice, to pay all or a portion of the interest payment due on April 1, 2026 in kind through similar capitalization.

The Second Amendment also adds a Minimum Consolidated Adjusted EBITDA covenant with stated dollar thresholds, including a minimum Consolidated Adjusted EBITDA requirement of $500,000 for the fiscal quarter ended June 30, 2026 and $1,000,000 for the fiscal quarter ended September 30, 2026. The Second Amendment also revises the consolidated senior net leverage ratio testing levels and related testing periods (including a specified maximum ratio of 20.00:1.00 for the fiscal quarter ended December 31, 2025 and a revised step-down schedule thereafter).

The Second Amendment amends the fixed charge coverage ratio to be measured at December 31, 2026 and must be not less than 1.20:1.00 for each of the trailing four fiscal quarters thereafter.

The Second Amendment further revises certain mandatory prepayment provisions relating to equity issuance proceeds. As amended, Net Cash Proceeds from Equity Issuances received on or after the Second Amendment Effective Date (other than Excluded Equity Issuances) are to be applied such that the first $6,000,000 may be retained for general corporate purposes, the next $4,000,000 must be applied to prepay the outstanding principal amount of the Term Loan, and Net Cash Proceeds received in excess of $10,000,000 are subject to additional mandatory prepayment requirements, including a requirement to prepay 50% of such excess proceeds if the Company’s Consolidated Senior Net Leverage Ratio as of the end of the most recent fiscal quarter ended on or before the date of receipt of such proceeds is equal to or greater than 2.50 to 1.00 and 0% of such excess proceeds if such ratio is less than 2.50 to 1.00. The Second Amendment also limits the Company’s ability to elect Term SOFR-based interest by providing that, effective February 1, 2026, all outstanding Term SOFR Rate Loans are automatically converted to Reference Rate Loans and the Company may not elect the Term SOFR rate option for any Loans until it has made principal reduction payments from and after the Second Amendment Effective Date in an aggregate amount of not less than $4,000,000.

The Second Amendment also revises the “Change of Control” definition to include, among other circumstances, the acquisition of beneficial ownership of more than 40% (increased from 30%) of the aggregate outstanding voting or economic power of the Company’s equity interests by any person or group (other than Jack Ross).

The Second Amendment also amends the Credit Agreement to include installment payment mechanics for certain legal expenses of ACP, amends the conditions under which the Company may make interest and principal payments on other indebtedness, and amends the prepayment provisions related to certain specified asset dispositions.

In connection with the Second Amendment, on March 24, 2026 the Company issued a common stock purchase warrant (the “Lender Warrant”) to Acme Credit Partners Fund I, LP (the “Holder”), a lender under the Credit Agreement. The Lender Warrant provides the Holder the right to purchase 3,000,000 shares of the Company’s common stock at an exercise price of $0.00001 per share. The Lender Warrant has a ten-year term and becomes exercisable upon the occurrence of a “Qualified Event of Default,” defined as the occurrence of any event of default under Section 8.1(a) of the Credit Agreement; the Lender Warrant terminates upon the indefeasible payment in full of all secured obligations under the Credit Agreement and related loan documents.

The Lender Warrant contains an issuance limitation providing that, until stockholder approval is obtained, the Company may not issue shares upon exercise of, after giving effect to such issuance, the Holder and its affiliates would beneficially own more than 19.9% of the Company’s outstanding common stock (the “Beneficial Ownership Limitation”). The Company has covenanted to seek stockholder approval for issuances in excess of the Beneficial Ownership Limitation at the Company’s next annual meeting of stockholders, to be held no later than June 30, 2026, and to use reasonable best efforts to solicit such approval and to cause the Company’s board of directors to recommend approval. The Lender Warrant also provides for a cashless (net) exercise feature following a Qualified Event of Default.

The Term Loan bears interest at the greatest of 6.0% per annum, the Federal Funds Rate plus 0.50% per annum, Term SOFR rate plus 1.00% and the rate last quoted by The Wall Street Journal as the “Prime Rate” in the United States, plus 7.5%, which resulted in an effective rate of 14.25% per annum as of March 31, 2026, and matures on May 30, 2029.

The Company recognized interest expense of $742,460 during the three months ended March 31, 2026. The Company accrued interest of $400,033, which is added to the principal balance.

ACP has informally alleged that a default has occurred under the Credit Agreement, but the Company has not received any formal written notice of the alleged default. The Company does not believe it is in default and, if a notice of the alleged default is delivered, it intends to vigorously dispute the alleged default and pursue all available rights and defenses. While the Company cannot predict the outcome of this matter, if the alleged default is formally declared and not resolved, it could result in remedies under the Credit Agreement, which could adversely affect the Company's liquidity.

The Company is required to make future payments as follows:

2026	$	350,000
2027	$	1,575,000
2028	$	1,400,000
2029	$	14,400,033

$3,024,000 November 2025 Accounts Receivable Advance:

On November 12, 2025, the Company entered into a cash advance agreement of $3,024,000 with Cedar Advance LLC for an advancement of working capital through the sale of receivables. The Company received $2,000,000 and recorded $1,024,000 as original issue discount. The advance bears a repayment rate of $84,000 per week with a total payment of $3,024,000. In conjunction with the advance, the Company issued 52,000 shares of common stock to the consultant who facilitated the facility and thus recognized $103,220 as financing cost.

The Company recognized interest expense of $777,785 during the three months ended March 31, 2026. During March 2026, this advance was consolidated into the advance detailed below. The outstanding advance balance at March 31, 2026 and December 31, 2025 was $0 and $2,436,000, with unamortized debt discount of $0 and $777,785 resulting in a net carrying amount of $0 and $1,658,215, respectively.

$4,032,000 March 2026 Accounts Receivable Advance:

On March 10, 2026, the Company entered into a cash advance agreement of $4,032,000 with Cedar Advance LLC for an advancement of working capital through the sale of receivables. The Company received $980,000 and repaid $1,680,000 of the November advance. The Company recorded $1,372,000 as original issue discount. The advance bears a repayment rate of $100,800 per week with a total payment of $4,032,000. In conjunction with the advance, the Company will issue 118,000 shares of common stock to the consultant who facilitated the facility and thus recognized $153,400 as financing cost.

The Company recognized total interest expense of $171,614 during the three months ended March 31, 2026. The outstanding advance balance at March 31, 2026 was $3,830,400, with unamortized debt discount of $1,353,786 resulting in a net carrying amount of $2,476,614.

Subsequent to March 31, 2026 the Company has made two payments of $201,600 on this advance.

As of March 31, 2026 and as of the date of filing this Report, the Company was in compliance with all applicable covenants under its debt agreements.

Note 12 – Stockholders’ Deficit

The total number of shares of all classes of capital stock which the Company is authorized to issue is 300,000,000 shares of common stock with $0.00001 par value.

As of both March 31, 2026 and December 31, 2025, there were 11,483,926 shares issued, and 11,303,853 shares outstanding.

Note 13 – Commitments and Contingencies

Litigation:

From time to time the Company may become a party to litigation in the normal course of business. Management believes that there are no current legal matters that would have a material effect on the Company’s financial position or results of operations.

License Revenue:

During 2025 the Company entered into a license agreement with a company to license its IP to territories in the United Arab Emirates and Turkey. The Company recognized $1,500,000 as licensing revenue in conjunction with this agreement during March 2025. Due to the instability in the countries, the licensee terminated the agreement in February 2026 with the Company, resulting in a reversal of the $1,500,000 license fee revenue during December 2025. Despite the termination, the Company is still pursuing the registration of the IP in those countries.

Note 14 – Stock Options and Warrants

The following table summarizes the options outstanding, option exercisability and the related prices for the shares of the Company’s common stock issued to employees and consultants under a stock option plan at March 31, 2026:

		Options Outstanding						Options Exercisable
Exercise Prices ($)		Number Outstanding		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price ($)		Number Exercisable		Weighted Average Exercise Price ($)
$	2.38		1,200,000		4.46	$	2.38		-	$	-

The stock option activity for the three months ended March 31, 2026 is as follows:

	Options		Weighted Average Exercise Price
Outstanding at December 31, 2025		1,200,000	$	2.38
Granted		-		-
Exercised		-		-
Expired or canceled		-		-
Outstanding at March 31, 2026		1,200,000	$	2.38
Exercisable at March 31, 2026		-	$	-

Stock-based compensation expense related to vested options was $116,307 during the three months ended March 31, 2026 and is recognized utilizing the straight-line method. Stock options outstanding as of March 31, 2026, as disclosed in the above table, have an intrinsic value of $0. Stock options exercisable as of March 31, 2026, as disclosed in the above table, have an intrinsic value of $0. As of March 31, 2026, unamortized stock-based compensation costs related to options was $1,144,243 and will be recognized over a period of 2.5 years.

The following table summarizes the changes in warrants outstanding and the related prices for the shares of the Company’s common stock issued at March 31, 2026:

		Warrants Outstanding						Warrants Exercisable
Exercise Price ($)		Number Outstanding		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price ($)		Number Exercisable		Weighted Average Exercise Price ($)
$	0.00001–11.70		3,156,000		3.16	$	0.43		156,000	$	8.69

The warrant activity for the three months ended March 31, 2026 is as follows:

	Warrants		Weighted Average Exercise Price
Outstanding at December 31, 2025		156,000	$	8.69
Granted		3,000,000		0.00001
Exercised		-		-
Expired or canceled		-		-
Outstanding at March 31, 2026		3,156,000	$	0.43
Exercisable at March 31, 2026		156,000	$	8.69

Stock warrants outstanding as of March 31, 2026, as disclosed in the above table, have an intrinsic value of $3,869,970. Stock warrants exercisable as of March 31, 2026, as disclosed in the above table, have an intrinsic value of $0.

Note 15 – Segments

Segment identification and selection is consistent with the management structure used by the Company’s CODM to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company’s management structure and method of internal reporting, the Company has one operating segment. The Company derives its revenue from the sale of nutraceuticals. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the segment and decides how to allocate resources based on net income that also is reported on the income statement as consolidated net income. The measure of segment assets is reported on the balance sheet as total consolidated assets. Significant segment expenses include retailer promotions, freight and fulfillment, marketing and salaries. The Company’s CODM reviews financial information presented and decides how to allocate resources based on net income. The Company does not have any intra-entity sales or transfers. The Company’s CODM does not review operating results on a disaggregated basis; rather, the CODM reviews operating results on an aggregated basis.

Net sales attributed to customers in the United States and foreign countries for the three months ended March 31, 2026 and 2025 were as follows:

	March 31, 2026		March 31, 2025
United States	$	5,221,880	$	7,454,724
Canada		227,580		656,877
Mexico		42,831		1,320
Other		414		57,613
	$	5,492,705	$	8,170,534

The Company’s net sales by product group for the three months ended March 31, 2026 and 2025 were as follows:

	March 31, 2026		March 31, 2025
Nutraceuticals	$	4,824,763	$	6,639,564
Beverages		667,942		30,970
License Revenue		-		1,500,000
	$	5,492,705	$	8,170,534

The Company’s net sales by major sales channel for the three months ended March 31, 2026 and 2025 were as follows:

	March 31, 2026		March 31, 2025
Online	$	1,787,085	$	2,761,845
Retail		3,705,620		5,408,689
	$	5,492,705	$	8,170,534

The Company’s significant segment expenses for the three months ended March 31, 2026 and 2025 were as follows:

	March 31, 2026		March 31, 2025
Retailer promotions	$	689,381	$	939,453
Freight and fulfillment		341,919		497,748
Online marketing		900,722		931,827
Salaries and benefits, marketing		432,559		328,174
Other selling and marketing		91,491		179,069
IT expenses		144,704		140,576
Salaries and benefits, non-marketing		1,059,304		567,993
Professional fees		254,270		163,768
Travel		160,733		155,120
Stock based compensation		160,057		-
Board of Directors compensation		31,250		-
Other general and administrative expenses		238,192		279,257
Amortization		33,333		33,333
	$	4,537,915	$	4,216,318

Long-lived assets (net) attributable to operations in the United States and foreign countries as of March 31, 2026 and December 31, 2025 were as follows:

	March 31, 2026		December 31, 2025
United States	$	116,667	$	150,000
Foreign countries		-		-
	$	116,667	$	150,000

Note 16 – Subsequent Events

Management evaluated all activities of the Company through the issuance date of the Company’s unaudited condensed consolidated financial statements and concluded that except as noted below, no subsequent events have occurred that would require adjustment or disclosure into the unaudited condensed consolidated financial statements.

During April 2026, the Company sold 3,278,030 shares under its ATM program, raising $2,673,201 in gross proceeds, which includes $80,261 of issuance expenses.

During April 2026, the Company issued 118,000 shares to a consultant that facilitated the loan facility.

During April 2026, the Company issued 200,000 shares for services rendered.

On May 11, 2026, the Company filed a Current Report on Form 8-K with the SEC regarding the entry into an equity purchase agreement (“ELOC”), pursuant to which the Company may issue and sell shares of its common stock from time to time, subject to market conditions and other factors.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

References in this report (the “Quarterly Report”) to “we,” “us” or the “Company” refer to Synergy CHC Corp. References to our “management” or our “management team” refer to our officers and directors. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Our actual results may differ significantly from the results, expectations and plans discussed in these forward-looking statements.

Special Note Regarding Forward-Looking Statements

This Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that are not historical facts, and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Quarterly Report including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding our financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations thereof and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 1, 2026 (the “Annual Report”) and the “Risk Factors” section of this Quarterly Report. Our securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, we disclaim any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Overview

We are a provider of consumer health care, beauty, and lifestyle products. Our current brand portfolio consists of two core brands: FOCUSfactor, a clinically-tested brain health supplement (this study was performed independently and is not related to any FDA-approved Investigational New Drug application) that has been shown to improve memory, concentration and focus, and Flat Tummy, a lifestyle brand that provides a suite of nutritional products to help women achieve their weight management goals.

Our management’s discussion and analysis of our financial condition and results of operations are only based on our current business and should be read in conjunction with our unaudited interim condensed consolidated financial statements and audited consolidated financial statements and accompanying notes thereto included elsewhere in this Quarterly Report. Key factors affecting our results of operations include revenues, cost of revenue, operating expenses and income and taxation.

Non-GAAP Financial Measures

We currently focus on EBITDA to evaluate our business relationships and our resulting operating performance and financial position. EBITDA is defined as net income plus interest expense, income tax expense, depreciation and amortization.

We believe that EBITDA, viewed in addition to, and not in lieu of, our reported results in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), provides useful information to investors.

	Three Months Ended March 31, 2026			Three Months Ended March 31, 2025
	(Unaudited)			(Unaudited)
Net (loss) income	$	(2,568,899	)	$	876,264
Interest income		(340	)		(13,882	)
Interest expense		2,012,121			1,095,369
Income tax benefit		(13,720	)		(11,460	)
Depreciation and amortization		33,333			33,333
EBITDA	$	(537,505	)	$	1,979,624

EBITDA is considered a non-GAAP financial measure. EBITDA represents earnings before interest, taxes, depreciation and amortization. Our definition of EBITDA might not be comparable to similarly titled measures reported by other companies.

Results of Operations for the Three Months Ended March 31, 2026 and March 31, 2025

During both the three months ended March 31, 2026 and 2025, we focused on developing our currently owned brands into new markets and by product extensions. Our objective is to grow our two targeted verticals (Nutraceuticals and Ready To Drinks (RTDs)) to provide a balanced and synergistic portfolio that drives consumer demand via multiple channels. Our Nutraceuticals vertical consists of FOCUSfactor, including RTDs, and Flat Tummy consumables.

Revenue

For the three months ended March 31, 2026, we had revenue of $5,492,705 from sales of our products, as compared to revenue of $8,170,534 for the three months ended March 31, 2025. The revenue is comprised of the following categories:

	March 31, 2026		March 31, 2025
Nutraceuticals	$	4,824,763	$	6,639,564
Beverages		667,942		30,970
License Revenue		-		1,500,000
	$	5,492,705	$	8,170,534

We had a decrease in Nutraceuticals revenue in the three months ended March 31, 2026 as compared to the three months ended March 31, 2025 due to a decrease in online sales. We had an increase in Beverages revenue in the three months ended March 31, 2026 as compared to the three months ended March 31, 2025 due to new retail distribution. We had a decrease in License Revenue in the three months ended March 31, 2026 as compared to the three months ended March 31, 2025 as that was a one-time item that did not repeat.

Cost of Revenue

For the three months ended March 31, 2026, our cost of revenue was $1,521,910. Our cost of revenue for the three months ended March 31, 2025, was $2,006,513. The decrease in cost of sales was primarily due to the decrease in revenue.

Gross Profit

Gross profit was $3,970,795, or 72% of revenue, for the three months ended March 31, 2026, as compared to gross profit of $6,164,021, or 75% of revenue, for the same period in 2025, a decrease of $2,193,226, or 36%. The decrease in gross profit is directly related to the license revenue in 2025.

Operating Expenses

Selling and Marketing Expenses

For the three months ended March 31, 2026, our selling and marketing expenses were $2,455,732 as compared to $2,876,271 for the three months ended March 31, 2025, which is primarily due to lower revenue.

General and Administrative Expenses

For the three months ended March 31, 2026, our general and administrative expenses were $2,048,850. For the three months ended March 31, 2025, our general and administrative expenses were $1,306,714. The increase is largely due to increased salaries and benefits, stock-based compensation, board compensation and professional fees.

Depreciation and Amortization Expenses

For both the three months ended March 31, 2026 and 2025, our depreciation and amortization expenses were $33,333.

Other Income and Expenses

For the three months ended March 31, 2026 and 2025 we had other income and expense items as follows:

	Three months ended March 31, 2026			Three months ended March 31, 2025

Interest expense	$	2,012,121		$	1,095,369
Interest income		(340	)		(13,882	)
Remeasurement loss on translation of foreign subsidiary		3,718			1,412
Total other expense	$	2,015,499		$	1,082,899

For the three months ended March 31, 2026, we had net interest expense of $2,012,121 as compared to $1,095,369 for the three months ended March 31, 2025. The increase is primarily due to an advance taken and the amortization of original debt discount on the May 2025 loan.

Net Income

For the three months ended March 31, 2026, our net loss was $2,568,899 as compared to a net income of $876,264 for the three months ended March 31, 2025 due to lower revenue.

Liquidity and Capital Resources

Overview

As of March 31, 2026, we had $292,115 cash on hand and restricted cash of $100,000 which is held for credit card collateral.

The Company considered the following:

●

At March 31, 2026, we had an accumulated deficit of $59,009,920.

●

At March 31, 2026, we had a decrease in net revenue of $2,677,829.

●

At March 31, 2026, we had a decrease in net income of $3,445,163.

●

At March 31, 2026, we had a working capital deficit of $503,862

●

During the three months ended March 31, 2026, we used $2,044,678 in operating activities.

Ordinarily, conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern relate to the entity’s ability to meet its obligations as they become due.

We evaluated our ability to meet our obligations as they become due within one year from the date that the unaudited condensed consolidated financial statements are issued by considering the following:

●

We entered into a second amendment with our current lender which adjusts various covenants and payment terms.

●

We laid off 13 employees in order to right size our overhead expenses.

●

We established an at-the-market (“ATM”) equity offering program pursuant to which we may issue and sell shares of our common stock from time to time, subject to market conditions and other factors. Subsequent to March 31, 2026, we have drawn down $2,673,201 in gross proceeds.

●

We have entered into an equity purchase agreement (“ELOC”), pursuant to which we may issue and sell shares of our common stock from time to time, subject to market conditions and other factors (see Note 16).

Cash Flows from Operating Activities

For the three months ended March 31, 2026, net cash used in operating activities was $2,044,678 compared to net cash used in operating activities of $822,781 for the three months ended March 31, 2025. This increase in net cash used by operating activities for the three months ended March 31, 2026 was primarily attributable to a decrease in net income.

For the three months ended March 31, 2026, net cash used in operating activities of $2,044,678 consisted of our net loss of $2,568,899 adjusted by:

Amortization of debt issuance cost	$	951,942
Depreciation and amortization		33,333
Stock based compensation		116,307
Foreign currency transaction gain		2,684
Remeasurement loss on translation of foreign subsidiary		3,718
Changes in operating assets and liabilities:
Accounts receivable		1,935,483
Inventory		355,895
Prepaid expense		(410,657	)
Prepaid expense, related party		(541,467	)
Income taxes payable		(2,297	)
Contract liabilities		(1,526	)
Accounts payable and accrued liabilities		(1,915,323	)
Accounts payable, related party		(3,871	)

For the three months ended March 31, 2025, net cash used in operating activities of $822,781 consisted of our net income of $876,264 adjusted by:

Amortization of debt issuance cost	$	406,841
Depreciation and amortization		33,333
Foreign currency transaction gain		(3,137	)
Remeasurement gain on translation of foreign subsidiary		(1,412	)
Changes in operating assets and liabilities:
Accounts receivable		940,519
Other receivables		144,637
Loan receivable, related party		(833	)
Inventory		(629,935	)
Prepaid expense		(114,787	)
Prepaid expense, related party		(195,913	)
Income taxes payable		(165,413	)
Contract liabilities		(24,216	)
Accounts payable and accrued liabilities		(2,218,041	)
Accounts payable, related party		129,312

Cash Flows from Investing Activities

For the three months ended March 31, 2026 and 2025, we used net cash of $0 in investing activities.

Cash Flows from Financing Activities

For the three months ended March 31, 2026, net cash used in financing activities was $307,600 compared to net cash provided by financing activities of $314,678 for the three months ended March 31, 2025. The decrease was attributable to decreased proceeds of notes.

Financing activities during the three months ended March 31, 2026 and 2025:

	Three months ended March 31, 2026			Three months ended March 31, 2025
Advances from related party	$	-		$	135,000
Repayment of notes payable, related party		(100,000	)		-
Proceeds from notes payable		2,660,000			1,496,250
Payment of loan financing fees		(55,000	)		-
Repayment of notes payable		(2,812,600	)		(1,316,572	)

Key Near-Term Initiatives

We intend to organically grow our current product lines by developing and launching new products and expanding into new markets. Specifically, for FOCUSfactor, we are working on increased distribution for our recently launched ready-to-drink beverage. Lastly, we intend to grow further through additional strategic acquisitions and we continue to evaluate opportunities and candidates that we believe fit well with our brand portfolio.

Off-Balance Sheet Arrangements

During the three months ended March 31, 2026, and during the year ended December 31, 2025, we had no off-balance sheet arrangements.

Inflation

The effect of inflation on our operating results was not significant in the three months ended March 31, 2026 or 2025.

Critical Accounting Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenue and expenses during the reported periods. The more critical accounting estimates include estimates related to revenue recognition and accounts receivable allowances. We also have other key accounting policies, which involve the use of estimates, judgments and assumptions that are significant to understanding our results, which are described in Note 2 to our unaudited condensed consolidated financial statements appearing elsewhere in this report.

Recent Accounting Pronouncements

Note 2 to our unaudited condensed consolidated financial statements appearing elsewhere in this report includes Recent Accounting Pronouncements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, we have elected not to provide the disclosure required by this item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Management, under the supervision and with the participation of the Chief Executive Officer and Chief Financial Officer, has conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Disclosure controls and procedures are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that as of the end of the period covered by this Quarterly Report, (i) the Company’s disclosure controls and procedures were not effective to ensure that material information relating to the Company is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (the “Commission”), and (ii) the Company’s controls and procedures have not been designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There has been no change in our internal control over financial reporting, as defined in Rules 13a-15(f) of the Exchange Act, during the quarter ended March 31, 2026, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II-OTHER INFORMATION

Item 1. Legal Proceedings.

We are not party to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incidental to the ordinary course of business. The outcome of litigation is inherently uncertain, and there can be no assurances that favorable outcomes will be obtained. In addition, regardless of the outcome, such proceedings or claims can have an adverse impact on us, which may be material because of defense and settlement costs, diversion of resources and other factors.

Item 1A. Risk Factors.

As a smaller reporting company under Rule 12b-2 of the Exchange Act, we are not required to include risk factors in this Quarterly Report. However, as of the date of this Quarterly Report, there have been no material changes with respect to those risk factors previously disclosed in the “Risk Factors” section of the Annual Report. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. We may disclose changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(a) None.

(b) None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

(a) None.

(b) None.

(c) During the quarter ended March 31, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report.

No.		Description of Exhibit

3.1		Articles of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. with the SEC on September 16, 2024)
3.2		Certificate of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed by Synergy CHC Corp. with the SEC on June 18, 2025)
3.3		Amended and Restated Bylaws (incorporated by reference to Exhibit 3.4 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. with the SEC on June 28, 2024)
4.1		Common Stock Purchase Warrant, dated as of March 24, 2026, by Synergy CHC Corp. to Acme Credit Partners Fund I, LP. (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K, filed by Synergy CHC Corp. with the SEC on March 25, 2026)
10.1		Second Amendment to Term Loan Credit Agreement, dated as of March 24, 2026, by and among Synergy CHC Corp. as Borrower, each subsidiary of the Borrower listed as a Guarantor therein, the lenders from time to time party thereto as Lenders and ACP Agency, LLC, as Collateral Agent and Administrative Agent (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed by Synergy CHC Corp. with the SEC on March 25, 2026)
31.1*		Rule 13a-14(a) Certification by Principal Executive Officer
31.2*		Rule 13a-14(a) Certification by Principal Financial and Accounting Officer
32.1**		Section 1350 Certification of Principal Executive Officer
32.2**		Section 1350 Certification of Principal Financial and Accounting Officer
101.INS*		Inline XBRL Instance Document
101.SCH*		Inline XBRL Taxonomy Extension Schema Document
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*		Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101)

Filed with this Report.

Furnished with this Report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SYNERGY CHC CORP.

Date: May 14, 2026	By:	/s/ Jack Ross
	Name:	Jack Ross
	Title:	Chief Executive Officer and Chairman
		(Principal Executive Officer)

http://fasb.org/srt/2026#ChiefExecutiveOfficerMember 0001562733 false 2026 Q1 --12-31 0001562733 2026-01-01 2026-03-31 0001562733 2026-05-11 0001562733 2026-03-31 0001562733 2025-12-31 0001562733 us-gaap:RelatedPartyMember 2026-03-31 0001562733 us-gaap:RelatedPartyMember 2025-12-31 0001562733 us-gaap:ProductMember 2026-01-01 2026-03-31 0001562733 us-gaap:ProductMember 2025-01-01 2025-03-31 0001562733 us-gaap:LicenseMember 2026-01-01 2026-03-31 0001562733 us-gaap:LicenseMember 2025-01-01 2025-03-31 0001562733 2025-01-01 2025-03-31 0001562733 us-gaap:CommonStockMember 2024-12-31 0001562733 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001562733 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001562733 us-gaap:TreasuryStockCommonMember 2024-12-31 0001562733 us-gaap:RetainedEarningsMember 2024-12-31 0001562733 2024-12-31 0001562733 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001562733 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001562733 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001562733 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0001562733 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001562733 us-gaap:CommonStockMember 2025-03-31 0001562733 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001562733 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001562733 us-gaap:TreasuryStockCommonMember 2025-03-31 0001562733 us-gaap:RetainedEarningsMember 2025-03-31 0001562733 2025-03-31 0001562733 us-gaap:CommonStockMember 2025-12-31 0001562733 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001562733 snyr:CommonStockToBeIssuedMember 2025-12-31 0001562733 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001562733 us-gaap:TreasuryStockCommonMember 2025-12-31 0001562733 us-gaap:RetainedEarningsMember 2025-12-31 0001562733 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001562733 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001562733 snyr:CommonStockToBeIssuedMember 2026-01-01 2026-03-31 0001562733 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0001562733 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-31 0001562733 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001562733 us-gaap:CommonStockMember 2026-03-31 0001562733 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001562733 snyr:CommonStockToBeIssuedMember 2026-03-31 0001562733 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001562733 us-gaap:TreasuryStockCommonMember 2026-03-31 0001562733 us-gaap:RetainedEarningsMember 2026-03-31 0001562733 snyr:OptionsToPurchaseCommonStockMember 2026-03-31 0001562733 snyr:OptionsToPurchaseCommonStockMember 2025-03-31 0001562733 snyr:OptionsToPurchaseCommonStockMember 2026-01-01 2026-03-31 0001562733 snyr:OptionsToPurchaseCommonStockMember 2025-01-01 2025-03-31 0001562733 2025-01-01 2025-12-31 0001562733 us-gaap:StockOptionMember 2026-01-01 2026-03-31 0001562733 us-gaap:StockOptionMember 2025-01-01 2025-03-31 0001562733 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001562733 us-gaap:WarrantMember 2025-01-01 2025-03-31 0001562733 snyr:PeriodendAUDUSDExchangeRateMember 2026-03-31 0001562733 snyr:PeriodendAUDUSDExchangeRateMember 2025-12-31 0001562733 snyr:PeriodendCADUSDExchangeRateMember 2026-03-31 0001562733 snyr:PeriodendCADUSDExchangeRateMember 2025-12-31 0001562733 snyr:AveragePeriodMXNUSDExchangeRateMember 2026-03-31 0001562733 snyr:AveragePeriodMXNUSDExchangeRateMember 2025-12-31 0001562733 snyr:AverageThreeMonthsAUDUSDExchangeRateMember 2026-03-31 0001562733 snyr:AverageThreeMonthsAUDUSDExchangeRateMember 2025-03-31 0001562733 snyr:AverageThreeMonthsCADUSDExchangeRateMember 2026-03-31 0001562733 snyr:AverageThreeMonthsCADUSDExchangeRateMember 2025-03-31 0001562733 snyr:AverageThreeMonthsMXNUSDExchangeRateMember 2026-03-31 0001562733 snyr:AverageThreeMonthsMXNUSDExchangeRateMember 2025-03-31 0001562733 snyr:BreakthroughProductsIncMember 2026-01-01 2026-03-31 0001562733 snyr:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-03-31 0001562733 snyr:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-12-31 0001562733 snyr:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-03-31 0001562733 snyr:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0001562733 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember snyr:VendorTwoMember 2026-01-01 2026-03-31 0001562733 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember snyr:VendorTwoMember 2025-01-01 2025-12-31 0001562733 snyr:PurchasesMember us-gaap:SupplierConcentrationRiskMember snyr:SupplierOneMember 2026-01-01 2026-03-31 0001562733 snyr:PurchasesMember us-gaap:SupplierConcentrationRiskMember snyr:SupplierTwoMember 2025-01-01 2025-03-31 0001562733 srt:ChiefExecutiveOfficerMember 2026-01-01 2026-03-31 0001562733 srt:ChiefExecutiveOfficerMember 2025-01-01 2025-03-31 0001562733 us-gaap:RelatedPartyMember 2026-01-01 2026-03-31 0001562733 srt:ChiefExecutiveOfficerMember 2026-03-31 0001562733 srt:ChiefExecutiveOfficerMember 2025-12-31 0001562733 us-gaap:RelatedPartyMember 2025-01-01 2025-03-31 0001562733 snyr:KnightTherapeuticsMember 2016-12-23 2016-12-23 0001562733 srt:ChiefExecutiveOfficerMember snyr:KnightTherapeuticsMember 2016-12-23 2016-12-23 0001562733 snyr:KnightTherapeuticsMember 2026-03-31 0001562733 snyr:KnightTherapeuticsMember 2025-12-31 0001562733 snyr:RoyaltyDistributionAgreementMember 2026-01-01 2026-03-31 0001562733 snyr:RoyaltyDistributionAgreementMember 2025-01-01 2025-12-31 0001562733 snyr:FebruaryTenTwoZeroTwoTwoLoanMember 2022-02-10 0001562733 snyr:FebruaryTenTwoZeroTwoTwoLoanMember 2022-09-09 0001562733 snyr:SecuritiesPurchaseAgreementsMember 2022-03-08 2022-03-08 0001562733 snyr:March82022LoansMember 2022-03-08 2022-03-08 0001562733 snyr:SecuritiesPurchaseAgreementsMember 2022-03-08 0001562733 snyr:ModificationAgreementMember 2024-03-31 2024-03-31 0001562733 snyr:May2025LoanMember 2025-05-30 2025-05-30 0001562733 2025-05-30 0001562733 snyr:March82022LoansMember 2026-03-31 0001562733 snyr:ReleaseAgreementMember 2025-04-28 2025-04-28 0001562733 snyr:JackRossMember 2026-01-01 2026-03-31 0001562733 snyr:May2025LoanMember 2025-05-30 0001562733 snyr:DelayedDrawFacilityMember 2025-05-30 0001562733 2025-05-30 2025-05-30 0001562733 snyr:May2025LoanMember 2026-01-01 2026-01-01 0001562733 snyr:May2025LoanMember 2026-07-01 2026-07-01 0001562733 srt:ScenarioForecastMember snyr:May2025LoanMember 2026-10-01 2026-10-01 0001562733 snyr:May2025LoanMember 2026-04-01 2026-04-01 0001562733 srt:ScenarioForecastMember 2027-01-01 2027-01-01 0001562733 snyr:May2025LoanMember 2025-05-30 2025-05-31 0001562733 snyr:May2025LoanMember 2025-06-01 2025-06-30 0001562733 snyr:May2025LoanMember 2026-01-01 2026-03-31 0001562733 snyr:May2025LoanMember 2026-03-31 0001562733 srt:ScenarioForecastMember snyr:May2025LoanMember 2026-07-01 2026-07-01 0001562733 srt:ScenarioForecastMember snyr:May2025LoanMember 2027-01-01 2027-01-01 0001562733 srt:ScenarioForecastMember snyr:May2025LoanMember 2027-04-01 2027-04-01 0001562733 snyr:May2025LoanMember 2026-09-30 2026-09-30 0001562733 snyr:May2025LoanMember 2026-10-01 0001562733 snyr:May2025LoanMember us-gaap:SubsequentEventMember 2026-06-30 0001562733 srt:ScenarioForecastMember snyr:May2025LoanMember 2026-09-30 0001562733 srt:MaximumMember snyr:May2025LoanMember 2026-01-01 2026-03-31 0001562733 srt:MinimumMember snyr:May2025LoanMember 2026-01-01 2026-03-31 0001562733 snyr:May2025LoanMember 2026-03-24 2026-03-24 0001562733 snyr:May2025LoanMember us-gaap:SecuredOvernightFinancingRateSofrMember 2026-01-01 2026-03-31 0001562733 snyr:November2025AccountsReceivableAdvanceMember 2025-11-12 0001562733 snyr:November2025AccountsReceivableAdvanceMember 2025-11-12 2025-11-12 0001562733 snyr:November2025AccountsReceivableAdvanceMember 2026-01-01 2026-03-31 0001562733 snyr:November2025AccountsReceivableAdvanceMember 2025-01-01 2025-12-31 0001562733 snyr:November2025AccountsReceivableAdvanceMember 2026-03-31 0001562733 snyr:November2025AccountsReceivableAdvanceMember 2025-12-31 0001562733 snyr:March2026AccountsReceivableAdvanceMember 2026-03-10 0001562733 snyr:March2026AccountsReceivableAdvanceMember 2026-03-10 2026-03-10 0001562733 snyr:March2026AccountsReceivableAdvanceMember 2026-01-01 2026-03-31 0001562733 snyr:March2026AccountsReceivableAdvanceMember 2026-03-31 0001562733 snyr:NotesPayableMember 2026-03-31 0001562733 snyr:NotesPayableMember 2025-12-31 0001562733 snyr:NotesMember 2026-03-31 0001562733 snyr:NotesMember 2025-12-31 0001562733 snyr:AccountsReceivableAdvanceMember 2026-03-31 0001562733 snyr:AccountsReceivableAdvanceMember 2025-12-31 0001562733 snyr:November122025AccountsReceivableAdvanceMember 2026-03-31 0001562733 snyr:November122025AccountsReceivableAdvanceMember 2025-12-31 0001562733 snyr:AccountsReceivableAdvanceOneMember 2026-03-31 0001562733 snyr:AccountsReceivableAdvanceOneMember 2025-12-31 0001562733 snyr:March102026AccountsReceivableAdvanceMember 2026-03-31 0001562733 snyr:March102026AccountsReceivableAdvanceMember 2025-12-31 0001562733 us-gaap:LoansPayableMember 2026-03-31 0001562733 us-gaap:LoansPayableMember 2025-12-31 0001562733 snyr:May2025LoanMember 2026-03-31 0001562733 snyr:May2025LoanMember 2025-12-31 0001562733 snyr:NotePayableTwoMember 2026-03-31 0001562733 snyr:NotePayableTwoMember 2025-12-31 0001562733 us-gaap:LicenseMember 2025-03-01 2025-03-31 0001562733 snyr:LicenseRevenueMember 2026-02-01 2026-02-28 0001562733 us-gaap:WarrantMember 2026-03-31 0001562733 srt:MinimumMember us-gaap:WarrantMember snyr:ElevenPointSevenZeroMember 2026-03-31 0001562733 srt:MaximumMember us-gaap:WarrantMember snyr:ElevenPointSevenZeroMember 2026-03-31 0001562733 us-gaap:WarrantMember snyr:ElevenPointSevenZeroMember 2026-03-31 0001562733 us-gaap:WarrantMember 2025-12-31 0001562733 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001562733 country:US 2026-01-01 2026-03-31 0001562733 country:US 2025-01-01 2025-03-31 0001562733 country:CA 2026-01-01 2026-03-31 0001562733 country:CA 2025-01-01 2025-03-31 0001562733 country:MX 2026-01-01 2026-03-31 0001562733 country:MX 2025-01-01 2025-03-31 0001562733 snyr:OtherMember 2026-01-01 2026-03-31 0001562733 snyr:OtherMember 2025-01-01 2025-03-31 0001562733 snyr:NutraceuticalsMember 2026-01-01 2026-03-31 0001562733 snyr:NutraceuticalsMember 2025-01-01 2025-03-31 0001562733 snyr:BeveragesMember 2026-01-01 2026-03-31 0001562733 snyr:BeveragesMember 2025-01-01 2025-03-31 0001562733 snyr:ConsumerGoodsMember 2026-01-01 2026-03-31 0001562733 snyr:ConsumerGoodsMember 2025-01-01 2025-03-31 0001562733 snyr:OnlineMember 2026-01-01 2026-03-31 0001562733 snyr:OnlineMember 2025-01-01 2025-03-31 0001562733 us-gaap:RetailMember 2026-01-01 2026-03-31 0001562733 us-gaap:RetailMember 2025-01-01 2025-03-31 0001562733 snyr:RetailerPromotionsMember 2026-01-01 2026-03-31 0001562733 snyr:RetailerPromotionsMember 2025-01-01 2025-03-31 0001562733 snyr:FreightAndFulfillmentMember 2026-01-01 2026-03-31 0001562733 snyr:FreightAndFulfillmentMember 2025-01-01 2025-03-31 0001562733 snyr:OnlineMarketingMember 2026-01-01 2026-03-31 0001562733 snyr:OnlineMarketingMember 2025-01-01 2025-03-31 0001562733 snyr:SalariesAndBenefitsMarketingMember 2026-01-01 2026-03-31 0001562733 snyr:SalariesAndBenefitsMarketingMember 2025-01-01 2025-03-31 0001562733 snyr:OtherSellingAndMarketingMember 2026-01-01 2026-03-31 0001562733 snyr:OtherSellingAndMarketingMember 2025-01-01 2025-03-31 0001562733 snyr:ITExpensesMember 2026-01-01 2026-03-31 0001562733 snyr:ITExpensesMember 2025-01-01 2025-03-31 0001562733 snyr:SalariesAndBenefitsNonMarketingMember 2026-01-01 2026-03-31 0001562733 snyr:SalariesAndBenefitsNonMarketingMember 2025-01-01 2025-03-31 0001562733 snyr:ProfessionalFeesMember 2026-01-01 2026-03-31 0001562733 snyr:ProfessionalFeesMember 2025-01-01 2025-03-31 0001562733 snyr:TravelMember 2026-01-01 2026-03-31 0001562733 snyr:TravelMember 2025-01-01 2025-03-31 0001562733 snyr:StockBasedCompensationMember 2026-01-01 2026-03-31 0001562733 snyr:StockBasedCompensationMember 2025-01-01 2025-03-31 0001562733 snyr:BoardOfDirectorsCompensationMember 2026-01-01 2026-03-31 0001562733 snyr:BoardOfDirectorsCompensationMember 2025-01-01 2025-03-31 0001562733 snyr:OtherGeneralAndAdministrativeExpensesMember 2026-01-01 2026-03-31 0001562733 snyr:OtherGeneralAndAdministrativeExpensesMember 2025-01-01 2025-03-31 0001562733 snyr:AmortizationMember 2026-01-01 2026-03-31 0001562733 snyr:AmortizationMember 2025-01-01 2025-03-31 0001562733 country:US 2026-03-31 0001562733 country:US 2025-12-31 0001562733 us-gaap:NonUsMember 2026-03-31 0001562733 us-gaap:NonUsMember 2025-12-31 0001562733 us-gaap:SubsequentEventMember 2026-04-01 2026-04-30 0001562733 snyr:LoanMember us-gaap:SubsequentEventMember 2026-04-01 2026-04-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure snyr:Segment iso4217:CAD

Synergy CHC Corp. 10-Q